ACR: Strontium ranelate cuts progression of knee OA

November 12, 2012
ACR: strontium ranelate cuts progression of knee OA
The osteoporosis therapeutic strontium ranelate reduces radiographic and radiological progression of knee osteoarthritis, according to a study presented at the annual meeting of the American College of Rheumatology, held from Nov. 10 to 14 in Washington, D.C.

(HealthDay)—The osteoporosis therapeutic strontium ranelate (SrRan) reduces radiographic and radiological progression of knee osteoarthritis, according to a study presented at the annual meeting of the American College of Rheumatology, held from Nov. 10 to 14 in Washington, D.C.

Jean-Yves Reginster, M.D., Ph.D., from the University of Liège in Belgium, and colleagues conduced a double-blind, placebo-controlled three-year study involving 1,371 patients (63 ± 7 years; 69 percent female) with symptomatic primary knee OA (Kellgren and Lawrence grade 2 or 3, joint space width [JSW] 3.5 ± 0.8 mm) who were randomized to receive SrRan (1 or 2 g/day) or placebo.

The researchers found that SrRan correlated with less progression of cartilage degradation and a significantly smaller decrease in JSW (−0.23 ± 0.56 mm with 1 g/day; −0.27 ± 0.63 mm with 2 g/day; and −0.37 ± 0.59 mm with placebo), with no difference between doses. SrRan at both doses also correlated with significantly less radiological and radioclinical progression. SrRan at the 2 g/day dose led to significant reductions in total Western Ontario and McMaster Universities Osteoarthritis Index score, including the pain and physical function subscores and . SrRan was well tolerated, with 17 percent of the patients in each group reporting a serious emergent adverse effect.

"Results of the present trial show also [SrRan's] ability to reduce the progression of osteoarthritis," Reginster said in a statement. "This could be a major step in the global management of musculo-skeletal disorders in the ."

Several authors disclosed to pharmaceutical companies, including Servier Laboratories, the manufacturer of strontium ranelate.

Explore further: BMI, post-exercise knee laxity change tied to OA progression

More information: Abstract
More Information

Related Stories

BMI, post-exercise knee laxity change tied to OA progression

August 21, 2012
(HealthDay) -- In patients with osteoarthritis (OA) of the knee, changes in knee joint laxity during stair climbing or other repetitive physical activity and baseline body mass index (BMI) are associated with disease progression, ...

Study looks at pain processing abnormalities in knee OA

September 17, 2012
(HealthDay)—For patients with knee osteoarthritis (K-OA), the lack of correlation between clinical pain and radiographic evidence of disease severity may be due to central sensitization, according to a study published online ...

Walking speed is a marker for knee osteoarthritis

March 20, 2012
(HealthDay) -- Slower walking speed may be a marker for identifying those at risk for knee osteoarthritis (OA), according to a study published online March 5 in Arthritis Care & Research.

Study indicates nanoparticles could help pain-relieving osteoarthritis drugs last longer

October 26, 2011
A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients ...

Donepezil found helpful in dementia with lewy bodies

July 31, 2012
(HealthDay) -- For patients with dementia with Lewy bodies (DLB), treatment with 5 or 10 mg/day donepezil is associated with significant cognitive, behavioral, and global function improvements, according to research published ...

Recommended for you

Fluid in the knee holds clues for why osteoarthritis is more common in females

June 26, 2017
Researchers have more evidence that males and females are different, this time in the fluid that helps protect the cartilage in their knee joints.

Biologics before triple therapy not cost effective for rheumatoid arthritis

May 29, 2017
Stepping up to biologic therapy when methotrexate monotherapy fails offers minimal incremental benefit over using a combination of drugs known as triple therapy, yet incurs large costs for treating rheumatoid arthritis (RA). ...

Drug for refractory psoriatic arthritis shows promise in clinical trial

May 24, 2017
In a pivotal phase-3 clinical trial led by a Stanford University School of Medicine investigator, patients with psoriatic arthritis for whom standard-of-care pharmaceutical treatments have provided no lasting relief experienced ...

Cross-species links identified for osteoarthritis

May 17, 2017
New research from the University of Liverpool, published today in the journal npj Systems Biology and Applications, has identified 'cell messages' that could help identify the early stages of osteoarthritis (OA).

Osteoarthritis could be prevented with good diet and exercise

May 12, 2017
Osteoarthritis can potentially be prevented with a good diet and regular exercise, a new expert review published in the Nature Reviews Rheumatology reports.

Rodents with trouble walking reveal potential treatment approach for most common joint disease

May 11, 2017
Maintaining the supply of a molecule that helps to nourish cartilage prevented osteoarthritis in animal models of the disease, according to a report published in Nature Communications online May 11.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.